Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer.
Adaptive radiotherapy
MR-guided radiotherapy
MR-linac
bladder cancer
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
22
05
2020
revised:
03
09
2020
accepted:
06
09
2020
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
Whole bladder magnetic resonance image-guided radiotherapy using the 1.5 Telsa MR-linac is feasible. Full online adaptive planning workflow based on the anatomy seen at each fraction was performed. This was delivered within 45 min. Intra-fraction bladder filling did not compromise target coverage. Patients reported acceptable tolerance of treatment.
Identifiants
pubmed: 33015380
doi: 10.1016/j.ctro.2020.09.002
pii: S2405-6308(20)30073-2
pmc: PMC7522378
doi:
Types de publication
Journal Article
Langues
eng
Pagination
46-51Subventions
Organisme : Department of Health
ID : ICA-SCL-2018-04-ST2-002
Pays : United Kingdom
Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The Royal Marsden Hospital and the Institute of Cancer Research are members of the Elekta MR-linac Consortium, which aims to coordinate international collaborative research relating to the Elekta Unity (MR-linac). Elekta (Elekta AB, Stockholm, Sweden) and Philips (Philips, Best, Netherlands) are commercial members of the MR-linac Consortium. Elekta financially supports consortium member institutions with research funding, education, and travel costs for consortium meetings. No commercial financial support was received from any organisation for the submitted work. AH, IH, AD, HB, LB, JC, CC, TH, RL, DM, HM, AM, JM, GS, and SN, have no other conflicts to disclose. HM also reports grant funding from a National Institute for Health Research and Health Education England (NIHR & HEE), Senior Clinical Lecturer award. TM also reports grant from Lister Institute of Preventive Medicine, outside the submitted work. EH is supported by a Cancer Research UK Centres Network Accelerator Award Grant (A21993) to the ART-NET consortium, other grants from Cancer Research UK during the conduct of the study; grants from Accuray Inc., grants from Varian Medical Systems Inc., outside the submitted work. UO also reports grants from Cancer Research UK. RH also reports non-financial support from Janssen, grants and personal fees from MSD, personal fees from Bristol Myers Squibb, grants from Cancer Research UK, other from Nektar Therapeutics, personal fees and non-financial support from Roche outside the submitted work. SH also reports non-financial support from Merck Sharp & Dohme (MSD), personal fees and non-financial support from Roche outside the submitted work.
Références
Strahlenther Onkol. 2003 Jan;179(1):21-30
pubmed: 12540981
Radiother Oncol. 2018 Mar;126(3):519-526
pubmed: 29277446
Cancer Med. 2019 May;8(5):2123-2132
pubmed: 30932367
Radiology. 2018 Feb;286(2):502-511
pubmed: 29206594
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):835-41
pubmed: 12573771
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):765-71
pubmed: 20932678
Radiother Oncol. 2014 Nov;113(2):254-9
pubmed: 25483834
BMJ Open. 2020 May 26;10(5):e037134
pubmed: 32461298
Strahlenther Onkol. 2020 Aug;196(8):691-698
pubmed: 32002567
J Adv Nurs. 2016 Jun;72(6):1368-80
pubmed: 26893007
Radiother Oncol. 2019 May;134:50-54
pubmed: 31005224
Clin Oncol (R Coll Radiol). 2013 Sep;25(9):549-56
pubmed: 23880296
Radiother Oncol. 2003 Dec;69(3):291-304
pubmed: 14644489
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):197-207
pubmed: 15093917
Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):261-9
pubmed: 23958147
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):115-122
pubmed: 28586948
Radiother Oncol. 2011 Apr;99(1):61-6
pubmed: 21429607
Acta Oncol. 2015;54(9):1474-82
pubmed: 26206517
J Med Phys. 2008 Oct;33(4):136-40
pubmed: 19893706
Tech Innov Patient Support Radiat Oncol. 2017 Jul 24;3-4:7-12
pubmed: 32095560
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):705-12
pubmed: 20472358
Phys Med Biol. 2013 May 7;58(9):2989-3000
pubmed: 23588253
Acta Oncol. 2019 Oct;58(10):1352-1357
pubmed: 31241387
Radiother Oncol. 2016 Jan;118(1):154-9
pubmed: 26631646
Acta Oncol. 2010 Oct;49(7):1069-76
pubmed: 20831498
Eur Urol. 2018 Nov;74(5):e109
pubmed: 30029821
Cureus. 2019 Dec 24;11(12):e6457
pubmed: 32025388
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1086-1094
pubmed: 31419510
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1022-30
pubmed: 27026308
Radiother Oncol. 2013 Dec;109(3):457-62
pubmed: 24100147
Cureus. 2018 Apr 5;10(4):e2431
pubmed: 29876153
Acta Oncol. 2014 Aug;53(8):997-1004
pubmed: 24957559
Clin Transl Radiat Oncol. 2019 Apr 02;18:54-59
pubmed: 31341976
Eur J Radiol. 2017 Oct;95:46-55
pubmed: 28987698
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):711-719
pubmed: 30201276
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):720-727
pubmed: 30197095